Cargando…
P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML TREATMENT.
Autores principales: | Xavier-Ferrucio, J., Luo, C., Angelini, G., Krishnamurthy, S., Patel, N., Pettiglio, M., Collingsworth, T., Isik, M., Ghodssi, A., Halfond, A., Etchin, J., Keschner, Y., Mundelboim, G., Tavares, P., Cummins, C., Falla, A., Hazelbaker, D., Paik, E., Sanchez, J., Ge, G., Lydeard, J., Lin, M. I., Chakraborty, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431284/ http://dx.doi.org/10.1097/01.HS9.0000848572.60330.2f |
Ejemplares similares
-
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
por: Lydeard, John R., et al.
Publicado: (2023) -
Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021) -
Chinese translation norms for 1,429 English words
por: Wen, Yun, et al.
Publicado: (2016) -
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021) -
Sa1429: CLINICAL AND PREDICTIVE FACTORS ASSOCIATED WITH NEED FOR TRANSJUGULAR PORTOSYSTEMIC SHUNT (TIPS) REVISION
por: Healey, Marcus A., et al.
Publicado: (2022)